Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression

Clinical Cancer Research

Volumn 21, Issue 5, 2015, Pages 1139-1150

  Kang, Min H ^a   Wang, Jing ^a   Makena, Monish R ^a   Lee, Joo Sang ^a   Paz, Nancy ^b   Hall, Connor P ^a   Song, Michael M ^a   Calderon, Ruben I ^a   Cruz, Riza E ^a   Hindle, Ashly ^a   Ko, Winford ^a   Fitzgerald, Jonathan B ^b   Drummond, Daryl C ^b   Triche, Timothy J ^c   Reynolds, C Patrick ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b MERRIMACK PHARMACEUTICALS   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DNA RNA HELICASE; FIRTECAN; HELICASE; IRINOTECAN; IRINOTECAN SUCROSOFATE; LIPOSOME; MESSENGER RNA; SLFN11 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG COMBINATION; NUCLEAR PROTEIN; SLFN11 PROTEIN, HUMAN; SUCROSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC KIT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TISSUE LEVEL; EVENT FREE SURVIVAL; EWING SARCOMA; EWING SARCOMA CELL LINE; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NONHUMAN; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPEATED DRUG DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; SOLID TUMOR; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION; GENETICS; IMMUNOLOGY; MACROPHAGE; MORTALITY; PATHOLOGY; SARCOMA, EWING; TISSUE DISTRIBUTION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; FEMALE; GENE EXPRESSION; HUMANS; LIPOSOMES; MACROPHAGES; MICE; NUCLEAR PROTEINS; SARCOMA, EWING; SUCROSE; TISSUE DISTRIBUTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928801150     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1882     Document Type: Article

References (46)

1. Sawada S, Okajima S, Aiyama R, Nokata K, Furuta T, Yokokura T, et al. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate- linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem Pharm Bull (Tokyo) 1991;39:1446-50.
2. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin formetastatic colorectal cancer. N Engl J Med 2000;343:905-14.
3. Houghton JA, Cheshire PJ, Hallman JD 2nd, Lutz L, Luo X, Li Y, et al. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. Clin Cancer Res 1996;2:107-18.
4. Rivory LP, Robert J. Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. Pharmacol Ther 1995;68:269-96.
5. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN- 38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991;51:4187-91.
6. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997;33:245-59.
7. Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, et al. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res 2004;10:6638-49.
8. Stewart CF, Zamboni WC, Crom WR, Houghton PJ. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing inmice. Cancer Chemother Pharmacol 1997;40:259-65.
9. Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen TL, et al.Phase-I andpharmacological studyof the novel topoisomerase-I inhibitor 7-Ethyl-10-[4-(1-Piperidino)-1-Piperidino]Carbonyloxycamptothecin (Cpt-11) administered as A 90-minute infusion every 3 weeks. Cancer Res 1994;54: 427-36.
10. Kehrer DF, SparreboomA, Verweij J, de Bruijn P, Nierop CA, van de Schraaf J, et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 2001;7:1136-41.
11. Drummond DC, Meyer O, Hong KL, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999;51:691-743.
12. Sadzuka Y, Hirotsu S,Hirota S. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11. Cancer Lett 1998; 127:99-106.
13. Drummond DC, Noble CO, Guo ZX, Hong K, Park JW, Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 2006;66:3271-7.
14. Noble CO, Krauze MT, Drummond DC, Yamashita Y, Saito R, Berger MS, et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res 2006;66:2801-6.
15. Dickinson PJ, LeCouteur RA, Higgins RJ, Bringas JR, Roberts B, Larson RF, et al. Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging. J Neurosurg 2008;108:989-98.
16. Krauze MT, Noble CO, Kawaguchi T, Drummond D, Kirpotin DB, Yamashita Y, et al. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol 2007;9:393-403.
17. Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol 2013;24: 1567-73.
18. Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, et al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer 2013;109:920-5.
19. Von Hoff D, Li CP, Wang-Gillam A, Bodoky G, Dean A, Jameson G, et al. NAPOLI-1: randomized phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer progressed on or following gemcitabine-based therapy. Ann Oncol 2014;25:ii105-ii106.
20. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
21. Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, Ballestrero A, et al. PutativeDNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A 2012;109:15030-5.
22. Owen LA, Lessnick SL. Identification of target genes in their native cellular context: an analysis of EWS/FLI in Ewing's sarcoma. Cell Cycle 2006;5: 2049-53.
23. Masters JR, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, Packer P, et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A 2001;98:8012-7.
24. Stoscheck CM. Quantitation of protein. In:Murray PD, editor.Methods in enzymology: guide to protein purification. Volume 182 ed. Waltham, Massachusetts: Academic Press; 1990. p. 50-68.
25. May WA, Grigoryan RS, Keshelava N, Cabral DJ, Christensen LL, Jenabi J, et al. Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines. PLoS ONE 2013;8:e80060.
26. Ozkaynak MF, Nolta J, Parkman R. In vitro purging of human rhabdomyosarcoma cells using 4-hydroperoxycyclophosphamide. Cancer Res 1990;50:1455-8.
27. Kouraklis G, Triche TJ, Wesley R, Tsokos M. Myc oncogene expression and nude mouse tumorigenicity and metastasis formation are higher in alveolar than embryonal rhabdomyosarcoma cell lines. Pediatr Res 1999;45: 552-8.
28. Taylor AC, Shu L, Danks MK, Poquette CA, Shetty S, Thayer MJ, et al. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol 2000;35:96-103.
29. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 2001;61:6185-93.
30. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24:148-54.
31. Frgala T, Kalous O, Proffitt RT, Reynolds CP. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 2007;6:886-97.
32. Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National cancer institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 2010;56:239-49.
33. KangMH, Wan Z, Kang Y, Sposto R, Reynolds CP. Mechanismof synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 2008;100: 580-95.
34. Grigoryan R, Keshelava N, Maurer BJ, Sun BC, Ludeman SM, Colvin OM, et al. Cyclophosphamide, but notmelphalan or carboplatin, synergistically enhanced topotecan activity against Ewing's family tumor cell lines in hypoxia. Proc Amer Assoc Cancer Res 2005;46:4712.
35. Satoh T, Hosokawa M. The mammalian caboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol 1998;38:257-88.
36. Akimoto K, Kawai A, Ohya K. Kinetic-studies of the hydrolysis and lactonization of camptothecin and its derivatives, Cpt-11 and Sn-38, in aqueous-solution. Chem Pharm Bull (Tokyo) 1994;42:2135-8.
37. Loos WJ, Verweij J, Gelderblom HJ, de Jonge MJ, Brouwer E, Dallaire BK, et al. Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans. Anticancer Drugs 1999; 10:705-10.
38. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818-22.
39. Mayer LD, Janoff AS. Optimizing combination chemotherapy by controlling drug ratios. Mol Intervent 2007;7:216-23.
40. Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. Aaps J 2007;9:E128-E147.
41. al-Sarireh B, Eremin O. Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth. J R Coll Surg Edinb 2000;45:1-16.
42. Guichard S, Terret C, Hennebelle I, Lochon I, Chevreau P, Frétigny E, et al. CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues. Br J Cancer 1999;80:364-70.
43. Xu G, Zhang W, Ma MK, McLeod HL. Human carboxylesterase 2 Is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 2002;8:2605-11.
44. Czuprynski CJ, Brown JF. Phagocytes from flora-defined and germfree athymic nude mice do not demonstrate enhanced antibacterial activity. Infect Immun 1985;50:425-30.
45. Kauer M, Ban J, Kofler R, Walker B, Davis S, Meltzer P, et al. A molecular function map of Ewing's sarcoma. PLoS ONE 2009;4:e5415.
46. Chen LT, Shiah HS, Lin PC, Lee JC, Su WC, Wang YW, et al. Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on first-line oxaliplatin-based chemotherapy. J Clin Oncol 2012;30:613.